As per reports, Johnson & Johnson (JNJ) is set to buy Momenta Pharmaceuticals Inc. for about $6.5 billion to strengthen its portfolio of drugs for hard-to-treat autoimmune diseases. Treatments specializing in autoimmune conditions have gained importance and have fetched billions of dollars in sales, like AbbVie Inc’s Humira, which is the world’s best-selling drug.
J&J’s Janssen unit will seek to move forward the development of Momenta’s experimental therapy, nipocalimab, late-stage testing for warm antibody hemolytic anemia. It is thought that eventually, it could be developed to treat several conditions.
Recently, J&J has sold some businesses and has shifted focus on better-performing products such as cancer treatments.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
Since you were interested in the this healthcare-related story please consider visiting the Atossa Therapeutics (ATOS) page at Vista Partners to learn about their progress in developing treatments for both COVID19 and breast cancer.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.